Inovio Pharmaceuticals, Inc. (INO) Stock Price

INOStock

$1.29−47.56%52W

Market Cap$133.38M

P/E—

PEG Ratio—

Div yield—

Beta1.67

INO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-43.68%

Price vs S&P 500 (4W)83.59%

VGM Score25.66

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)1.19x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-81.47%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)-38.68%

Gross Margin (TTM)58.85%

Net Profit Margin (TTM)-25107.34%

EPS (TTM)$-1.70

10-Day Avg Trading Volume4.33M

EPS Excl Extra (TTM)$-1.70

Revenue Growth (5Y)-61.18%

EPS (Annual)$-1.81

ROI (Annual)-352.53%

Gross Margin (Annual)60.13%

Net Profit Margin (5Y Avg)-43066.73%

Cash / Share (Quarterly)$0.54

ROA (Last FY)-114.31%

Revenue Growth TTM (YoY)-69.99%

EBITD / Share (TTM)$-1.48

ROE (5Y Avg)-165.21%

Operating Margin (TTM)-27701.47%

Cash Flow / Share (Annual)$-1.29

P/B Ratio15.34x

P/B Ratio (Quarterly)19.91x

Net Income / Employee (Annual)$-758,400

EV / Revenue (TTM)235.95x

Net Interest Coverage (TTM)-43.65x

ROA (TTM)-129.81%

EPS Incl Extra (Annual)$-1.81

Current Ratio (Annual)1.40x

Quick Ratio (Quarterly)0.99x

3-Month Avg Trading Volume3.30M

52-Week Price Return-47.56%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$5.15

P/S Ratio (Annual)1424.37x

Asset Turnover (Annual)0.00x

52-Week High$2.98

Operating Margin (5Y Avg)-44274.27%

EPS Excl Extra (Annual)$-1.81

CapEx CAGR (5Y)-28.42%

Tangible BV CAGR (5Y)-2.96%

26-Week Price Return-31.75%

Quick Ratio (Annual)1.34x

13-Week Price Return-0.77%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.04x

Enterprise Value$66.80M

Revenue / Share Growth (5Y)-69.97%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-58.86%

Revenue / Employee (Annual)$600

Inventory Turnover (Annual)3.19x

Pretax Margin (Annual)-130005.97%

Cash / Share (Annual)$0.85

3-Month Return Std Dev107.17%

Gross Margin (5Y Avg)63.72%

Net Income / Employee (TTM)$-758,300

ROE (Last FY)-352.53%

Net Interest Coverage (Annual)-1.04x

EPS Basic Excl Extra (Annual)$-1.81

P/FCF (TTM)6.36x

Receivables Turnover (TTM)0.11x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.70

Receivables Turnover (Annual)0.11x

ROI (TTM)-201.57%

P/S Ratio (TTM)328.76x

Pretax Margin (5Y Avg)-43057.61%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.15

Price vs S&P 500 (52W)-66.12%

Year-to-Date Return-25.86%

5-Day Price Return3.20%

EPS Normalized (Annual)$-1.81

ROA (5Y Avg)-85.92%

Net Profit Margin (Annual)-130005.97%

Month-to-Date Return90.55%

Cash Flow / Share (TTM)$-0.62

EBITD / Share (Annual)$-1.82

Operating Margin (Annual)-132877.43%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-160.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.70

P/TBV (Quarterly)1.19x

P/B Ratio (Annual)4.96x

Inventory Turnover (TTM)2.11x

Pretax Margin (TTM)-25107.34%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)-2.72%

Beta1.67x

Revenue / Share (TTM)$0.00

ROE (TTM)-201.57%

52-Week Low$0.56

vGradeD

gGradeF

mGradeC

vgmGradeD

INO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.24	-$0.24	+0.57%(+$0.00)
Q1 2026	May 13, 2026	-$0.33	-$0.31	+4.71%(+$0.02)
Q4 2025	Mar 12, 2026	-$0.34	-$0.28	+19.59%(+$0.07)
Q3 2025	Nov 10, 2025	-$0.48	-$0.87	-82.77%(-$0.39)
Q2 2025	Aug 12, 2025	-$0.62	-$0.61	+1.29%(+$0.01)

INO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

3.89

3.75

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
INOInovio Pharmaceuticals, Inc.	D	F	C	$1.29
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies for HPV-associated diseases, cancer, and infectious diseases. The company's proprietary electroporation technology enables targeted delivery and enhanced immunogenicity of its DNA medicine candidates.